Tenofovir exalidex(CMX157)

产品编号: DC26022 Featured
Tenofovir exalidex(CMX157)
结构式
911208-73-6
此产品仅供科研所需,我们不出售给病人
​我们将匹配市场上最好的价格给您
Email:order@dcbio.cn
免费咨询电话:4008862077
我们的合作伙伴:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
中国地区超过5000个高品质化合物库存
应用领域
Tenofovir exalidex is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir.
Cas No.: 911208-73-6
名称: 3-(hexadecyloxy)propyl hydrogen ((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate
别名: Tenofovir exalidex; HDP-Tenofovir; Tenofovir; CMX-157; CMX157; CMX 157
SMILES: C[C@@H](OCP(O)(OCCCOCCCCCCCCCCCCCCCC)=O)CN1C=NC2=C(N)N=CN=C12
分子式: C28H52N5O5P
分子量: 569.37
纯度:
保存条件: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description:
In Vivo:
In Vitro:
References: Tenofovir exalidex, also known as HDP-Tenofovir and CMX-157, is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir. Tenofovir exalidex results in decreased circulating levels, lowering systemic exposure and thereby reducing the potential for renal and bone side effects. Potential Advantages of Tenofovir exalidex over Tenofovir include: Increased efficacy by boosting bioavailability; Takes advantage of natural lipid uptake mechanisms; Decreased renal toxicity by reduced circulating TFV; 97-fold more active against HBV in vitro.
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
TITLE DOWNLOAD
MSDS_1281_DC26022_911208-73-6
COA
LOT NO. DOWNLOAD
产品编号 产品名称 应用领域
DC26116 Poloppin Poloppin is a cell-active, small molecule inhibitor of protein-protein interaction via the Polo-box domain (PBD) of the mitotic Polo-like kinase (PLK) with IC50 of 26.9 uM (PLK1) in FP assays.
DC26114 GpTx-1 GpTx-1 is a potent, selective, 34-residue peptide antagonist of Nav1.7 sodium channel with IC50 of 10 nM, displays 20- and 1000- fold selectivity over NaV1.4 and NaV1.5..
DC26113 LSP4–2022 LSP4–2022 is a novel potent, selective, brain-penetrant mGluR4 agonist with EC50 of 0.11 uM in cell-based assays.
DC26109 MCL0129 tetrahydrochloride MCL0129 is a selective, potent melanocortin-4 receptor (MC4R) antagonist with Ki of 7.9 nM, without affinity for MC1 and MC3.
DC26100 SR-16507 SR-16507 is a potent full agonist of ORL1 receptor (NOP receptor) and partial agonist of mu-opioid receptor with Ki of 5.22 nM and 1.07 nM, respectively.
DC26091 PF-05198007 PF-05198007 is a potent, state-dependent, subtype selective Nav1.7 inhibitor with IC50 of 9 nM, no significant activity against Nav1.5 (IC50>10 uM).
DC26081 JTE-852 JTE-852 is a novel potent, selective, ATP-competitive Syk kinase inhibitor with IC50 of 1.25/1.28 nM for human/rat Syk, respectively.
DC26080 GX-674 GX-674 is a potent, selective Nav1.7 inhibitor with IC50 of 0.1 nM.
DC26078 GNE-616 GNE-616 (GNE616) is a highly potent, metabolically stable, subtype selective inhibitor of Nav1.7 with Ki of 0.79 nM (hNav1.7).
DC26071 BMS 814580 A highly potent, subtype-selective melanin concentrating hormone receptor 1 (MCHR1) inhibitor with Ki of 17 nM, without inhibitory activity for MCHR2 at 10 uM.